Know Cancer

or
forgot password

Phase II Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes on Patients With Unresectable Non Small Cell Lung Cancer Responding to Induction Chemotherapy


Phase 2
18 Years
70 Years
Open (Enrolling)
Both
Non Small Cell Lung Cancer

Thank you

Trial Information

Phase II Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes on Patients With Unresectable Non Small Cell Lung Cancer Responding to Induction Chemotherapy


Inclusion Criteria:



- advanced unresectable non small cell lung cancer

- responding or stabilizer after induction chemotherapy

Type of Study:

Interventional

Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Progression free survival

Outcome Time Frame:

4 months

Safety Issue:

Yes

Authority:

France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Study ID:

IGR Dex2

NCT ID:

NCT01159288

Start Date:

December 2009

Completion Date:

December 2014

Related Keywords:

  • Non Small Cell Lung Cancer
  • Advanced unresectable non small cell lung cancer
  • Responding or stabilized after induction chemotherapy
  • Carcinoma, Non-Small-Cell Lung
  • Lung Neoplasms

Name

Location